## Edgar Filing: Cara Therapeutics, Inc. - Form 4

Cara Therap	beutics, Inc.								
Form 4	. ~								
June 17, 20								OMB A	PPROVAL
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									3235-0287
Check the if no lon subject to Section Form 4 Form 5			NGES IN SECUI 16(a) of th	Estimated burden hou response	Expires: January 31, 2005 Estimated average burden hours per response 0.5				
obligatio may cor <i>See</i> Inst 1(b).	ons Section 17(	(a) of the l	Public U	Jtility Hol	ding Coi		of 1935 or Secti		
(Print or Type	Responses)								
1. Name and 2 Menzaghi I	2. Issuer Name <b>and</b> Ticker or Trading Symbol Cara Therapeutics, Inc. [CARA]				5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (	Middle)		of Earliest T		- ,	(Cho	eck all applicabl	e)
C/O CARA INC., 1 PA	(Month/Day/Year) 06/15/2015				Director       10% Owner         Officer (give title       Other (specify below)         below)       below)         VP-Research & Development				
SHELTON	4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Tah	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of. or Beneficia	llv Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	ed Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3,	ies (A) or of (D)	5. Amount of	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect
Reminder: Re	port on a separate line	e for each cl	ass of sec	urities bene	Perso inforr requi	ons who res nation cont red to resp	or indirectly. spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)
					displa numb		nuy valid OMB co	ontrol	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: Cara Therapeutics, Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/	Day/Year)	(Instr. 8)	Acquired or Dispose (D) (Instr. 3, 4 and 5)	ed of				
					Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option	\$ 10.82	06/15/2015			A	60,000		<u>(1)</u>	06/15/2025	Common Stock	60,000
(Right to Buy)										Stock	
Reporting Owners											
Reporting Owner Name / Address		<b>Relationships</b> Director 10% Owner Officer						Other			
Menzaghi Frederique Ph.D. C/O CARA THERAPEUTICS, INC. 1 PARROTT DRIVE SHELTON, CT 06484		VP-Research & Development									
Signat	ures										
/s/Darren DeStefano, Attorney-in-Fact		06/1	7/2015								
<u>**</u> Signatu	re of Reporting Per	rson	I	Date							

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares shall vest and become exercisable in a series of 48 successive equal monthly installments measured from February 1, 2015, subject to the reporting person's continuous service with the issuer as of each such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.